tbuckley/cabot-search huggingface dataset:
Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.
Authors: Steven D. Gore, Stephen B. Baylin, Tianna Dauses, Michael R. Grever, Anchalee Jiemjit, Jasper Manning, Carole B. Miller, Anthony J. Murgo, James A. Zwiebel, James G. Herman
Journal: Blood (2004)
Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection
Authors: Alexis Talbot, Laurence Gérard, Raphael Szalat, David Boutboul, Stephanie Harel, Anne Lazareth, Marion Malphettes, Bouchra Asli, Lionel Galicier, Claire Fieschi, Eric Oksenhendler, Jean Paul Fermand, Bertrand Arnulf
Journal: Blood (2013)
Prognostic Impact of Early and Late 18fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Prior to Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed or Refractory Hodgkin Lymphoma
Authors: Alexander Claviez, Regine Kluge, Christine Mauz-Körholz, Dirk Hasenclever, Martina Stiefel, Daniel Clauss, Lars Kurch, Arndt Borkhardt, Hans-Wilhelm Müller, Brigitte Strahm, Wolfgang Weber, Andreas E Kulozik, Uwe Haberkorn, Heribert Jürgens, Otmar Schober, Thomas Klingebiel, Frank Grünwald, Eva Bergsträsser, Gustav von Schulthess, Dieter Körholz
Journal: Blood (2011)
TCT-216 Impact of Dual versus Triple Antiplatelet Therapy on 1-year Clinical Outcomes in Symptomatic Peripheral Arterial Disease Patients following Percutaneous Transluminal Angioplasty
Authors: Sang-Ho Park, Seung-Woon Rha, Ung Jun, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jin oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2015)
Polyostotic Fibrous Dysplasia in McCune-Albright Syndrome Demonstrated on 68Ga-DOTATATE PET/CT
Authors: Grace Hennessy, Deepa Shetty, Han Loh, Chuong Bui, Ken Le, Robert Mansberg
Journal: Clinical Nuclear Medicine (2016)

A 33-year-old woman with McCune-Albright syndrome was referred for a Ga-DOTATATE PET/CT study for evaluation and staging of a biopsy-proven pancreatic tail neuroendocrine tumor. The scan demonstrated intense focal octreopeptide uptake corresponding to the known neuroendocrine tumor at the pancreatic tail/splenic hilum. There was no evidence of octreopeptide-avid metastases. Diffuse octreopeptide uptake was demonstrated in multiple bones involving the right side of the skeleton. The concurrent CT demonstrated corresponding expansile lucent changes consistent with the known fibrous dysplasia.
Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems
Authors: Jurjen Versluis, Myriam Labopin, Dietger Niederwieser, Gérard Socié, Richard F Schlenk, Noel Milpied, Arnon Nagler, Didier Blaise, Vanderson Rocha, Jan Cornelissen, Mohamad Mohty
Journal: Blood (2012)
Pain Medication: Time to First Dose in Sickle Cell Acute Care in Two Settings of a Large Urban Hospital
Authors: Bonnye Johnson, Dawn Lei, Nicholas F Furtado, Saman K. Hashmi, Robert Molokie, Joseph DeSimone, Johara Hassan, Michel Gowhari, Tara Gordon, Darcel Dowell, Glenda Pendarvis, Heather Prendergast, Victor R. Gordeuk, Lewis L. Hsu
Journal: Blood (2012)
TCT-811 Comparison of Outcomes of Different Revascularization Strategies for Femoro-popliteal Disease: A Network Meta-analysis
Authors: Won Yu Kang, Michael J. Lipinski, Ricardo O. Escarcega, Nelson L. Bernardo, Umberto Campia, Romain Didier, Rebecca Torguson, Ron Waksman
Journal: Journal of the American College of Cardiology (2015)
The impact of a "just culture" environment on the reporting of medication errors/near misses.
Authors: Cheryl A. Steele, Shani Michelle Weber
Journal: Journal of Clinical Oncology (2016)

131 Background: UPMC CancerCenter is a large outpatient medical oncology network of 25 locations, located within a 200 mile radius of Pittsburgh, PA. The Cancer Center administers approximately 118,000 treatments and 38,000 injections per year by 200 oncology nurses. Staff members have been strongly encouraged for years to report not only medication errors but also near misses. Despite the continual encouragement it was suspected that the actual number of reported medication errors and near misses was frequently underreported. Methods: In 2012 a Safety Culture Survey comprised of 43 questions was administered to all clinical staff in order to evaluate the comfort level of the staff in speaking up about medication safety issues. Cancer Center leadership wanted to convert from a ‘no blame’ response to errors to a ‘Just Culture’ environment that includes not only a robust accountability model but a model for addressing system and behavioral risks both before and after events occur. This survey was again repeated in 2014. At the conclusion of each survey period nursing leaders conducted on site in-services at every Cancer Center location. Individual site results along with Cancer Center aggregate results were reviewed with all participants. Participants were challenged to identify action items that could contribute to improving patient safety. Results: The results indicated a decrease in the number of respondents who reported feeling fearful of reporting in in 2012 (33%) compared to 2014 (28%). The number of reported near misses increased by 181% while actual error reported increased by 45% from 2012 to 2014. Conclusions: Staff quickly realized that should an error occur they would be treated fairly when they report medication errors. The staff also realized the positive impact that reporting has on patient safety. The conversion to a “Just Culture’ environment significantly increased the number of medication errors reported as a result of open communication and the implementation of a well-established system of accountability.
GW27-e1148 Angiotensin 1-7 Protects against Ox-LDL -Induced Endothelial Endoplasmic Reticulum Stress and Apoptosis
Authors: Yang Zhiming, Jingjing Xue, Huiyu Yang, Bin Liang, Yanan Zhao, Zhiming Yang
Journal: Journal of the American College of Cardiology (2016)
O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)
Authors: F. Pietrantonio, C. Cremolini, L. Rimassa, S. Lonardi, A. Mennitto, F. Morano, D. Iacono, R. Berenato, M. Caporale, M. Niger, F. Marmorino, S. Bozzarelli, F. Bergamo, D. Rossini, M. Baretti, F. Battaglin, M. Bonotto, F. Loupakis, F. de Braud, R. Miceli
Journal: Annals of Oncology (2016)
TCT-491 Incidence of Peri-Procedural Myocardial Infarction after Bifurcation Percutaneous Coronary Intervention According to Different Definitions: Insight from the Tryton IDE randomized trial
Authors: Maciej Lesiak, Antonio L. Bartorelli, Maik J. Grundeken, Philippe Genereux, Joanna J. Wykrzykowska, Dominic P. Francese, Indulis Kumsars, Annapoorna Kini, Thierry Lefevre, Hector M. Garcia-Garcia, Geza Fontos, Pieter R. Stella, Imre Ungi, Linn L. Laak, Aaron Kaplan, Yoshinobu Onuma, Martin Leon, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2015)
C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma.
Authors: Marcin Majka, Artur Jurczyszyn, Anna Zebzda, Wojciech Czogala, Ewa Lesko, Zbigniew Rudzki, Jolanta Gozdzik, Teresa Wolska-Smolen, Aleksander B. Skotnicki, Mariusz Z. Ratajczak
Journal: Blood (2005)
Primary systemic therapy for locally advanced breast cancer using sequential dDoxorubicin followed by dose dense paclitaxel and cyclophosphamide
Authors: J. Carpenter, S. Davidson, L. Talley
Journal: Journal of Clinical Oncology (2004)

871 Background:Dose dense chemotherapy has been shown to be more effective than less frequently administered therapy in the adjuvant setting but has not been extensively evaluated as primary systemic therapy. Methods:A series of 34 patients with locally advanced breast cancer was treated with primary systemic therapy consisting of 3 doses of doxorubicin 60 mg/M 2 i.v. every 3 weeks followed by dose dense paclitaxel 175 mg/M 2 i.v. every 2 weeks, and cyclophosphamide 600 mg/M 2 i.v. every 2 weeks, then by operation and by radiotherapy in most. Results:Clinical complete response (cCR) was seen in 24 (71%). At the time of operation, 13/34 (38%) had a complete pathologic response (pCR), although 5 of these had persisting noninvasive carcinoma in the resected tissue and 2 had pathologically positive axillary nodes. Four additional patients had only microscopical residual invasive carcinoma in the resected breast tissue. One grade IV granulocytopenia but no febrile neutropenia was seen. There was no other toxicity greater than grade II except for one grade III anemia. No cardiotoxicity was observed. With a median followup of 3 years (range 1–6 years) no recurrences have occurred in patients who experienced pCR or who had only microscopical residual carcinoma. Conclusions:These results suggest that a sequential dose dense regimen is at least comparably effective and is considerably less toxic than doxorubicin/cyclophosphamide followed by docetaxel. The lack of early recurrences in patients with no residual or only microscopic residual invasive carcinoma at operation indicates that these responses are likely to be durable. No significant financial relationships to disclose.
Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study
Authors: Laurie H. Sehn, Andre Goy, Fritz C. Offner, Giovanni Martinelli, Jonathan Friedberg, Susan F. Lasserre, Gregg Fine, Oliver W. Press
Journal: Blood (2011)
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
Authors: Adil I. Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard Joseph, Tara C. Gangadhar, Roxana Dronca, Amita Patnaik, Hassane Zarour, Charlotte Roach, Grant Toland, Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, Scot Ebbinghaus, Omid Hamid
Journal: Journal of Clinical Oncology (2016)

Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1). This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks. Tumor response was assessed every 12 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review. Primary outcome was objective response rate. Secondary outcomes included progression-free survival (PFS) and overall survival (OS). Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by a clinical trial immunohistochemistry assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clinical outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered positive. Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-positive tumors. Demographic and staging variables were equally distributed among PD-L1-positive and -negative patients. An association between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was observed ( P < .001 for each). Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, respectively. Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-negative tumors may also achieve durable responses.
GW27-e1103 An Updated Systematic Review and Meta-analysis of the Short- and Long-term Outcomes of Percutaneous Coronary Intervention for Patients with Severe Left Ventricular Systolic Dysfunction
Authors: Zixiang Yu, Nuremanguli Abudukeremu, Siew-Pang Chan, Yi-Ning Yang, Xiao-Mei Li, Fen Liu, Yitong Ma
Journal: Journal of the American College of Cardiology (2016)
90Y Digital PET/CT Imaging Following Radioembolization
Authors: Chadwick L. Wright, Jun Zhang, Katherine Binzel, Evan J. Wuthrick, Michael V. Knopp
Journal: Clinical Nuclear Medicine (2016)

Imaging of Y internal pair production with conventional photomultiplier detector PET technology has been previously reported for patients with malignant/metastatic liver lesions treated with Y radioembolization (RE). We present a 54-year-old man with unresectable liver metastases from rectal carcinoma (involving the right and left lobes) who was referred for Y RE and subsequently imaged using new solid-state digital photon counting technology (Vereos 64 Time-of-Flight PET/CT; Philips, Cleveland, OH). Despite imaging at 26 hours following RE, digital PET/CT provides improved image quality and Y-to-background contrast as well as accurate visualization of Y biodistribution when compared with Bremsstrahlung SPECT/CT.
Efficacy and safety of sequential use of everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with bevacizumab (BEV) with or without interferon (INF) therapy: Overall survival (OS) result from the European AVATOR retrospective study.
Authors: Antoine Thiery-Vuillemin, Christine Theodore, Lutz Jacobasch, Jorg Schmitz, Aline Guillot, Christos Papandreou, Christos E. Emmanouilides, Stefano Chong Hun Kim, Meryem Ktiouet, Nadia Kelkouli, Thierry Nguyen
Journal: Journal of Clinical Oncology (2013)

e15607 Background: EVE (Afinitor) has demonstrated activity in the treatment of mRCC after failure of VEGF-targeted tyrosine kinase inhibitors. However, to this date, there is no published data evaluating its activity/safety after failure of first line BEV-based therapy. Methods: Our non-interventional multicenter international study reports retrospective data on EVE in routine use. Eligible patients had mRCC; were given EVE after 1 prior first-line systemic therapy with BEV +/- INF. The data were provided by each center and centralized. Results: Here are the final results: 20 sites included 43 pts between 2011 and 2012, with 42 evaluable patients. Baseline patient characteristics included median age of 69 [38-90] years old; 64.3% male; 97.5% with prior nephrectomy. First-line therapy was BEV + INF in 69% of patients, BEV only for 31%. Prognostic groups at the time of EVE initiation according to Heng (1) and to MSKCC (2) were respectively: (1): good 25%, intermediate 59.4% and poor prognosis 15.6% and (2) good 28.1%, intermediate 56.3% and poor 15.6%. Median duration of treatment with first line therapy was 7.5 months, and it was discontinuated for disease progression in 61.9 % of pts. From initiation of first line therapy 53.3 % of patients were alive at 32 months. Median OS was not reached for the second line; with 52.3% patients who had not progressed 8 months after the start of everolimus. Overall response rate was 9.5 % and disease stabilization rate was 50%. At least one adverse event (AE) occurred in 73.8 % of pts with 13 serious AEs. All grade common AEs were consistent with the toxicity profile of EVE with 31 % of stomatitis, 16.7 % of pneumonitis, 31 % of fatigue. Conclusions: This study provided encouraging results for the activity and safety profile of EVE in this second line mRCC setting after 1 prior first-line therapy with bevacizumab-based regimen. Further studies with larger numbers of pts are planned based on these novel findings.
GW27-e0937 Assessing the feasibility and quality of shared decision making in China: evaluating a clinical encounter intervention for Chinese patients
Authors: Huang Rongchong, Song Xiantao, Wu Jian, Huang Wei, Ding Huaiyu, Zhang Dongfeng, Liu Yongxian, Lu Yafei, Aaron Leppin, Michael Gionfriddo, Kasey Boehmer, Henry H. Ting, Victor M. Montori, Huang Rongchong
Journal: Journal of the American College of Cardiology (2016)
Efficacy of Liposomal Bupivacaine Infiltration on the Management of Total Knee Arthroplasty
Authors: Bryan Sakamoto, Shelly Keiser, Russell Meldrum, Gene Harker, Andrew Freese
Journal: JAMA Surgery (2016)

Liposomal bupivacaine is a novel extended-duration anesthetic that has recently been used for local infiltration in total knee arthroplasty (TKA). Athough liposomal bupivacaine is widely used, it is unknown if the benefits justify the cost in the veteran population at our institution.To evaluate a change in practice: the effect of local infiltration of liposomal bupivacaine on perioperative outcomes in patients undergoing primary TKA.A retrospective cohort study was conducted among patients who underwent primary TKA at a Veterans Affairs Medical Center before (March 3, 2013-March 2, 2014) and after (March 3, 2014-March 2, 2015) the implementation of liposomal bupivacaine for local infiltration in TKA.Drug utilization evaluation of liposomal bupivacaine for local infiltration in TKA.Use of opioids after discharge from the postanesthesia care unit.Among 199 patients, those who received liposomal bupivacaine after primary TKA (mean [SD] age, 65.3 [6.9] years; 93 males and 5 females) had a reduced median opioid use in the first 24 hours after surgery compared with those who did not receive liposomal bupivacaine (mean [SD] age, 64.9 [8.4] years; 95 males and 6 females; [intravenous morphine equivalents, 12.50 vs 22.50 mg; P = .001]). The use of patient-controlled analgesia was also reduced among patients who received liposomal bupivacaine vs those who did not (49 vs 91; P < .001). A reduction in the use of antiemetics was observed in the first 24 hours after surgery (13 vs 34; P = .001) and in the postanesthesia care unit among those who received liposomal bupivacaine vs those who did not (4 vs 20; P = .001). The number of patients in the postanesthesia care unit with no pain was improved among those who received liposomal bupivacaine vs those who did not (44 vs 19; P < .001). Although median (interquartile range) pain scores in the postanesthesia care unit were improved among patients who received liposomal bupivacaine vs those who did not (4.0 [0.0-6.6] vs 5.5 [3.0-7.5]; P = .001), patients who received liposomal bupivacaine had greater median (interquartile range) pain scores 48 hours (5.5 [4.0-7.0] vs 5.0 [3.0-6.0]; P = .01), 72 hours (5.0 [4.0-6.0] vs 4.0 [2.0-6.0]; P = .002), and 96 hours (5.0 [3.0-6.5] vs 4.0 [1.0-5.0]; P = .003) after surgery than those who did not receive liposomal bupivacaine. There was no difference in the median length of stay between the 2 groups. Institutional cost savings was estimated at $27 000 per year.Local infiltration of liposomal bupivacaine reduces use of opioids in the first 24 hours after primary TKA. Similarly, reduction in antiemetic use and improved postoperative pain are also seen in the first 24 hours after surgery but are limited to this time frame. Furthermore, a positive institutional cost savings was observed.
Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice
Authors: Helena A White, Robert F Miller, Anton L Pozniak, Marc C I Lipman, Iain Stephenson, Martin J Wiselka, Manish Pareek
Journal: Thorax (2016)

Latent TB infection (LTBI) screening and treatment in HIV-positive individuals in the UK is advocated by the British HIV Association (BHIVA) and National Institute for Health and Care Excellence (NICE), although each recommends differing strategies. We undertook an evaluation of UK practice, relating the responses to the local HIV/TB disease burden. 162 of 188 (86%) UK geographical areas responded; only 93/162 (57.4%) offer LTBI testing with considerable heterogeneity in practice, and no difference in HIV/TB burden between areas offering testing and those who do not. Only 33/93 (35.5%) and 6/93 (6.5%) reported full compliance with BHIVA and NICE guidance respectively. A uniform national guideline is required.
Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.
Authors: Robert J. Kreitman, Evgeny Arons, Sapolsky Jeffrey, Laura Roth, Hong Zhou, Maryalice Stetler-Stevenson, Wyndham H. Wilson, Mark Raffeld, David J. P. FitzGerald, Ji Fei, Ramy Ibrahim, Ira Pastan
Journal: Blood (2012)
GMC is urged to reinstate doctor struck off for role in “shaken baby” cases
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Over 250 doctors, academics, and lawyers have urged the UK General Medical Council to reconsider its decision to strike off a paediatric neuropathologist for repeatedly giving misleading and dishonest evidence to courts in so called “shaken baby” cases.

Waney Squier, a consultant neuropathologist at the John Radcliffe Hospital in Oxford, acted as an expert witness for parents accused of injuring or killing their babies by deliberate acts. Squier raised the possibility of different causes, such as choking, …
TCT-248 Benefit Of Triple Antiplatelet Treatment In Elderly Patients With ST Elevation Myocardial Infarction (STEMI) Undergone Primary Percutaneous Coronary Intervention (PCI): Data From INTERSTELLAR Cohort
Authors: Tae-Hoon Kim, Ho-Jun Jang, Jeonggeun Moon, Pyung Chun Oh, Jon Suh, Hyun Woo Park, Sang-Don Park, Sung Woo Kwon, Woong Chol Kang
Journal: Journal of the American College of Cardiology (2015)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Authors: Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V Sequist, Mark M Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi
Journal: The Lancet Oncology (2016)
Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).
Authors: Mikkael A. Sekeres, Aristoteles Giagounidis, Hagop M. Kantarjian, Ghulam J. Mufti, Pierre Fenaux, Catherine Jia, Allen S. Yang, Uwe Platzbecker
Journal: Blood (2012)
AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia
Authors: Erika Keeton, Sangeetha Palakurthi, Marat Alimzhanov, Michael Grondine, Yuching Chen, Jeffrey Brown, Kristen McEachern, Yichen Cao, Dharmaraj Chinnappan, Minhui Shen, Les Dakin, Xiao Zheng, Michelle Lamb, Allan Wu, Huawei Chen, Paul Lyne, Dennis Huszar
Journal: Blood (2011)
The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2nd) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS)
Authors: Elias Jabbour, Hagop M. Kantarjian, Jenny Shan, Susan O'Brien, Alfonso Quintas-Cardama, Guillermo Garcia-Manero, Jorge Cortes
Journal: Blood (2010)